US Patent

US11253478 — Reduction of flake-like aggregation in nanoparticulate active agent compositions

Method of Use · Assigned to Alkermes Pharma Ireland Ltd · Expires 2030-05-26 · 4y remaining

Vulnerability score 64/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method to reduce flake-like aggregation in nanoparticulate active agent compositions, such as those used in a drug product.

USPTO Abstract

This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3318 — Mobic

Patent Metadata

Patent number
US11253478
Jurisdiction
US
Classification
Method of Use
Expires
2030-05-26
Drug substance claim
No
Drug product claim
Yes
Assignee
Alkermes Pharma Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.